JAK-IN-25

CAT: 0804-HY-153440-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-153440-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
JAK-IN-25 (compound 19) is a potent JAK inhibitor with IC50s of 6 nM, 21 nM, 8 nM, 1051 nM for TYK2, JAK1, JAK2, JAK3, respectively. JAK-IN-25 inhibits human whole blood IL-12 (HEB IL-12) with an IC50 of 28 nM. JAK-IN-25 has the potential for cancer research[1].
CAS Number
[2127110-22-7]
UNSPSC
12352005
Target
JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/jak-in-25.html
Purity
98.44
Solubility
DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C1=NN2C=C(C3=CN(CC4=CC=C(C=C4)OC)N=C3)NC(C2=C1)=O)OC
Molecular Formula
C19H17N5O4
Molecular Weight
379.37
References & Citations
[1]Matthew Frank Brown, et al. Pyrazolo[1,5-a]pyrazin-4-yl derivatives. US20230045252A1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
JAK1; JAK2; JAK3; Tyk2

Related Products

CatalogName
HY-143444-01JAK-IN-20
HY-151262-01JAK-IN-23
HY-111471JAK-IN-5
HY-157011JAK-IN-33
HY-144057JAK-IN-17
HY-111749JAK-IN-4
HY-18301-01JAK-IN-35
HY-139807-01JAK-IN-14
HY-154994-01JAK-IN-30
HY-161621JAK-IN-37

Alternative Products

CatalogName
MF-0156602-01JAK-IN-25
MBS3844679-01JAK-IN-4
MBS3844669-01JAK-IN-3
MBS3615024-01JAK-IN-11
MF-0146614-01JAK-IN-17
MF-0099746-01JAK-IN-30
MF-0157080-01JAK-IN-29
MF-0117521-01JAK-IN-37
MF-0094222-01JAK-IN-14
MBS5820772JAK-IN-27

Popular Products